# SNY catalysts: Sanofi PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sny/catalysts

> Sanofi (SNY) has 134 upcoming catalysts. The next is the venglustat PDUFA date, November 25, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SNY?

Sanofi (SNY) has 134 upcoming catalysts. The next is the venglustat PDUFA date, November 25, 2026. Press release filed with the SEC (EX-99): "The target action date for the FDA decision is November 25, 2026." [Calendar and source filings](https://sec-api.dev/companies/sny/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001121404-26-000008, https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm (retrieved 2026-11-12). Last confirmed 2026-07-30. Cite: https://sec-api.dev/companies/sny/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Sanofi |
| Ticker | SNY (Nasdaq) |
| SEC CIK | 1121404 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sny |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 27, 2016 | [Adlyxin (lixisenatide) FDA approval](https://sec-api.dev/pdufa/lixisenatide) | SNY |  | completed, approved | "BLA208471 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160727, review_priority STANDARD; sponsor_name SANOFI-AVENTIS US; product ADLYXIN (LIXISENATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208471%22)) |
| November 21, 2016 | [Soliqua 100/33 (insulin glargine; lixisenatide) FDA approval](https://sec-api.dev/pdufa/insulin-glargine-lixisenatide) | SNY |  | completed, approved | "BLA208673 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20161121, review_priority PRIORITY; sponsor_name SANOFI-AVENTIS US; product SOLIQUA 100/33 (INSULIN GLARGINE; LIXISENATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208673%22)) |
| May 22, 2017 | [Kevzara (sarilumab) FDA approval](https://sec-api.dev/pdufa/sarilumab) | SNY |  | completed, approved | "BLA761037 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170522, review_priority STANDARD; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22)) |
| December 11, 2017 | [Admelog (insulin lispro) FDA approval](https://sec-api.dev/pdufa/insulin-lispro) | SNY |  | completed, approved | "BLA209196 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20171211, review_priority STANDARD; sponsor_name SANOFI-AVENTIS US; product ADMELOG (INSULIN LISPRO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA209196%22)) |
| March 2, 2020 | [Sarclisa (isatuximab-irfc) FDA approval](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761113 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200302, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product SARCLISA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761113%22)) |
| March 12, 2020 | [Thyrogen (thyrotropin alfa) label expansion decision](https://sec-api.dev/pdufa/thyrotropin-alfa) | SNY |  | completed, approved | "BLA020898 SUPPL-65 (Efficacy): submission_status AP, submission_status_date 20200312, review_priority STANDARD; sponsor_name GENZYME; product THYROGEN (THYROTROPIN ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA020898%22)) |
| November 12, 2020 | [Fexinidazole (fexinidazole) complete response letter (CRL)](https://sec-api.dev/pdufa/fexinidazole) | SNY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214429_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| December 18, 2020 | [Jevtana Kit (cabazitaxel) label expansion decision](https://sec-api.dev/pdufa/cabazitaxel) | SNY |  | completed, approved | "NDA201023 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority PRIORITY; sponsor_name SANOFI AVENTIS US; product JEVTANA KIT (CABAZITAXEL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA201023%22)) |
| March 11, 2021 | [Fabrazyme (agalsidase beta) label expansion decision](https://sec-api.dev/pdufa/agalsidase-beta) | SNY |  | completed, approved | "BLA103979 SUPPL-5309 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority STANDARD; sponsor_name GENZYME; product FABRAZYME (AGALSIDASE BETA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103979%22)) |
| March 31, 2021 | [Sarclisa (isatuximab-irfc) label expansion decision](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761113 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20210331, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product SARCLISA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761113%22)) |
| April 30, 2021 | [Aubagio (teriflunomide) label expansion decision](https://sec-api.dev/pdufa/teriflunomide) | SNY |  | completed, approved | "NDA202992 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20210430, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product AUBAGIO (TERIFLUNOMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202992%22)) |
| July 16, 2021 | [Fexinidazole (fexinidazole) FDA approval](https://sec-api.dev/pdufa/fexinidazole) | SNY |  | completed, approved | "NDA214429 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210716, review_priority PRIORITY; sponsor_name SANOFI; product FEXINIDAZOLE (FEXINIDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214429%22)) |
| July 30, 2021 | [Adlyxin (lixisenatide) label expansion decision](https://sec-api.dev/pdufa/lixisenatide) | SNY |  | completed, approved | "BLA208471 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210730, review_priority STANDARD; sponsor_name SANOFI-AVENTIS US; product ADLYXIN (LIXISENATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA208471%22)) |
| August 6, 2021 | [Nexviazyme (avalglucosidase alfa-ngpt) FDA approval](https://sec-api.dev/pdufa/avalglucosidase-alfa-ngpt) | SNY |  | completed, approved | "BLA761194 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210806, review_priority PRIORITY; sponsor_name GENZYME CORP; product NEXVIAZYME (AVALGLUCOSIDASE ALFA-NGPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761194%22)) |
| July 18, 2022 | [Clolar (clofarabine) label expansion decision](https://sec-api.dev/pdufa/clofarabine) | SNY |  | completed, approved | "NDA021673 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20220718, review_priority STANDARD; sponsor_name GENZYME; product CLOLAR (CLOFARABINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021673%22)) |
| August 31, 2022 | [Xenpozyme (olipudase alfa-rpcp) FDA approval](https://sec-api.dev/pdufa/olipudase-alfa-rpcp) | SNY |  | completed, approved | "Xenpozyme \| Olipudase alfa \| 8/31/2022 \| To treat Acid Sphingomyelinase DeficiencyPress Release (FDA Archive)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| February 28, 2023 | [Kevzara (sarilumab) label expansion decision](https://sec-api.dev/pdufa/sarilumab) | SNY |  | completed, approved | "BLA761037 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20230228, review_priority PRIORITY; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22)) |
| May 2023 | [AYVAKIT® (avapritinib) FDA approval](https://sec-api.dev/pdufa/avapritinib) | SNY | advanced SM in June 2021 and indolent SM in May 2023 | completed, approved | "It was FDA approved for the treatment of advanced SM in June 2021 and indolent SM in May 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525160799/d82392dex991.htm)) |
| September 15, 2023 | [Nexviazyme (avalglucosidase alfa-ngpt) label expansion decision](https://sec-api.dev/pdufa/avalglucosidase-alfa-ngpt) | SNY |  | completed, approved | "BLA761194 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20230915, review_priority STANDARD; sponsor_name GENZYME CORP; product NEXVIAZYME (AVALGLUCOSIDASE ALFA-NGPT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761194%22)) |
| October 23, 2023 | [Multaq (dronedarone hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dronedarone) | SNY |  | completed, approved | "NDA022425 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20231023, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product MULTAQ (DRONEDARONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022425%22)) |
| November 1, 2023 | [Sarclisa (isatuximab-irfc) label expansion decision](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761113 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20231101, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product SARCLISA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761113%22)) |
| March 7, 2024 | [Caprelsa (vandetanib) label expansion decision](https://sec-api.dev/pdufa/vandetanib) | SNY |  | completed, approved | "NDA022405 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240307, review_priority STANDARD; sponsor_name GENZYME CORP; product CAPRELSA (VANDETANIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022405%22)) |
| June 10, 2024 | [Kevzara (sarilumab) label expansion decision](https://sec-api.dev/pdufa/sarilumab) | SNY |  | completed, approved | "BLA761037 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20240610, review_priority STANDARD; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22)) |
| Sep 2024 | [Sanofi FDA approval](https://sec-api.dev/companies/sny/catalysts) | SNY |  | completed, approved | "In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the first line setting." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312524260686/d793925dex991.htm)) |
| September 20, 2024 | [Sarclisa (isatuximab-irfc) label expansion decision](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761113 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority PRIORITY; sponsor_name SANOFI AVENTIS US; product SARCLISA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761113%22)) |
| October 25, 2024 | [Sarclisa (isatuximab-irfc) label expansion decision](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761113 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20241025, review_priority STANDARD; sponsor_name SANOFI AVENTIS US; product SARCLISA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761113%22)) |
| February 14, 2025 | [Merilog (insulin aspart-szjj) FDA approval](https://sec-api.dev/pdufa/insulin-aspart-szjj) | SNY |  | completed, approved | "BLA761325 ORIG-1: submission_status AP, submission_status_date 20250214, review_priority STANDARD; sponsor_name SANOFI-AVENTIS U.S. LLC; product MERILOG (INSULIN ASPART-SZJJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761325%22)) |
| March 28, 2025 | [Qfitlia™ (fitusiran) FDA approval](https://sec-api.dev/pdufa/fitusiran) | SNY | To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release | completed, approved | "Qfitlia \| fitusiran \| 3/28/2025 \| To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| June 11, 2025 | [Doxercalciferol (doxercalciferol) label expansion decision](https://sec-api.dev/pdufa/doxercalciferol) | SNY |  | completed, approved | "NDA020862 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20250611, review_priority STANDARD; sponsor_name SANOFI; product HECTOROL (DOXERCALCIFEROL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020862%22)) |
| June 11, 2025 | [Doxercalciferol (gz427397) primary completion](https://sec-api.dev/pdufa/doxercalciferol-gz427397) | SNY | Secondary Hyperparathyroidism-Chronic Kidney Disease | withdrawn | "NCT02859896 (Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02859896)) |
| June 11, 2025 | [Low dose (ld) rsvt vaccine primary completion](https://sec-api.dev/pdufa/low-dose-ld-rsvt-vaccine) | SNY | RSV Immunisation; Healthy Volunteers | withdrawn | "NCT06705140 (A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-08-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06705140)) |
| June 18, 2025 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Rheumatoid Arthritis | completed | "NCT06073093 (A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06073093)) |
| June 20, 2025 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm)) |
| June 30, 2025 | [Sanofi FDA approval](https://sec-api.dev/companies/sny/catalysts) | SNY |  | completed, approved | "Sanofi's collaboration partner Novavax, Inc. announced that the US FDA had approved the biologics license application ("BLA) for Nuvaxovid for active immunization to prevent coronavirus disease 2019 ("COVID-19") caused by severe acute respiratory syndrome coronavirus 2 ("SARS-CoV-2") in adults aged 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, diabetes, obesity, smoking)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex992.htm)) |
| 2H 2025 | [Itepekimab topline data readout](https://sec-api.dev/pdufa/itepekimab) | SNY | COPD in two phase 3 studies AERIFY-1 | scheduled | "Itepekimab is currently being explored in patients with COPD in two phase 3 studies AERIFY-1 (clinical study identifier: NCT04701983) and AERIFY-2 (clinical study identifier: NCT04751487) with the readout anticipated in H2 2025, and in one phase 2 study, AERIFY-3 (clinical study identifier: NCT05326412), with the readout anticipated in H2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525082251/d941050dex991.htm)) |
| July 23, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06130566 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06130566)) |
| August 6, 2025 | [SAR447537 primary completion](https://sec-api.dev/pdufa/sar447537) | SNY | Alpha 1-Antitrypsin Deficiency; Emphysema | completed | "NCT05856331 (Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-06 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05856331)) |
| August 21, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06224348 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06224348)) |
| August 29, 2025 | [Wayrilz (rilzabrutinib) PDUFA date](https://sec-api.dev/pdufa/rilzabrutinib) | SNY |  | completed, approved | "Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312524278124/d913939dex992.htm)) |
| August 29, 2025 | [Wayrilz (rilzabrutinib) FDA approval](https://sec-api.dev/pdufa/rilzabrutinib) | SNY |  | completed, approved | "Wayrilz \| rilzabrutinib \| 8/29/2025 \| To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroidsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| September 16, 2025 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Bronchiectasis | completed | "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280391)) |
| September 18, 2025 | [Rsvt vaccine primary completion](https://sec-api.dev/pdufa/rsvt-vaccine) | SNY | RSV Immunization | withdrawn | "NCT06397768 (Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06397768)) |
| September 24, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Alopecia Areata | withdrawn | "NCT06444451 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06444451)) |
| September 28, 2025 | [Tolebrutinib PDUFA date](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | delayed | "Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525077305/d942506dex991.htm)) |
| October 1, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06015308 (A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015308)) |
| October 2, 2025 | [Cerezyme (imiglucerase) primary completion](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher's Disease Type III | completed | "NCT05222906 (Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222906)) |
| October 9, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Hidradenitis Suppurativa | withdrawn | "NCT06028230 (A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06028230)) |
| October 21, 2025 | [Bivv020 (sar445088) primary completion](https://sec-api.dev/pdufa/bivv020-sar445088) | SNY | Transplant Rejection | completed | "NCT05156710 (BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156710)) |
| October 23, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Atopic Dermatitis | withdrawn | "NCT06058156 (Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058156)) |
| November 14, 2025 | [Tolebrutinib primary completion](https://sec-api.dev/pdufa/tolebrutinib) | SNY | Primary Progressive Multiple Sclerosis | completed | "NCT04458051 (Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04458051)) |
| November 14, 2025 | [Menacyw conjugate vaccine primary completion](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT06284915 (Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284915)) |
| November 15, 2025 | [Meningococcal polysaccharide (serogroups a, c, y, and w) tetanus toxoid conjugate vaccine primary completion](https://sec-api.dev/pdufa/meningococcal-polysaccharide-serogroups-a-c-y-and-w-tetanus-toxoid-conjugate-vac) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT05794230 (Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-15 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05794230)) |
| November 25, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06181435)) |
| December 4, 2025 | [Rsvt vaccine primary completion](https://sec-api.dev/pdufa/rsvt-vaccine) | SNY | RSV Immunisation | withdrawn | "NCT06252285 (Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252285)) |
| December 17, 2025 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05206773 (A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05206773)) |
| December 22, 2025 | [SARCLISA® (isatuximab) primary completion](https://sec-api.dev/pdufa/isatuximab) | SNY | Relapsed/Refractory Multiple Myeloma | completed | "NCT05704049 (A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05704049)) |
| December 23, 2025 | [Tolebrutinib complete response letter (CRL)](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219624_20251223.pdf%22)) |
| December 25, 2025 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever | completed | "NCT07222059 (Phase 3 Single Arm, Open Study on vYF in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-25 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222059)) |
| December 26, 2025 | [Eliglustat gz385660 primary completion](https://sec-api.dev/pdufa/eliglustat-gz385660) | SNY | Gaucher's Disease Type I; Gaucher's Disease Type III | completed | "NCT03485677 (Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-26 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03485677)) |
| December 28, 2025 | [Tolebrutinib PDUFA date](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyond the previously communicated revised US target action date of December 28, 2025; (ii) further guidance from the FDA was expected by the end of the first quarter of 2026; and (iii) in response to an FDA request, Sanofi had submitted an expanded access protocol for tolebrutinib in nrSPMS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525332163/d65502dex991.htm)) |
| 2026 | [Itepekimab topline data readout](https://sec-api.dev/pdufa/itepekimab) | SNY |  | scheduled | "Finally, itepekimab is being explored in a phase 2 study (clinical study identifier: NCT06280391) in bronchiectasis, with the readout anticipated in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525082251/d941050dex991.htm)) |
| January 12, 2026 | [Cerezyme (imiglucerase) label expansion decision](https://sec-api.dev/pdufa/imiglucerase) | SNY |  | completed, approved | "BLA020367 SUPPL-123 (Efficacy): submission_status AP, submission_status_date 20260112, review_priority STANDARD; sponsor_name GENZYME; product CEREZYME (IMIGLUCERASE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA020367%22)) |
| January 12, 2026 | [Nvx-cov2705 primary completion](https://sec-api.dev/pdufa/nvx-cov2705) | SNY | COVID-19; SARS-CoV-2 Infection | completed | "NCT07079670 (Safety and Immunogenicity of NVX-CoV2705): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07079670)) |
| January 13, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is January 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm)) |
| January 20, 2026 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | completed | "NCT07002060 (Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07002060)) |
| January 29, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06454240 (A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06454240)) |
| February 10, 2026 | [SAR443122 primary completion](https://sec-api.dev/pdufa/sar443122) | SNY | Colitis Ulcerative | completed | "NCT05588843 (Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05588843)) |
| February 12, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Dermatitis Atopic | completed | "NCT06790121 (A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790121)) |
| February 23, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | completed | "NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06102005)) |
| March 2, 2026 | [Avalglucosidase alfa primary completion](https://sec-api.dev/pdufa/avalglucosidase-alfa) | SNY | Glycogen Storage Disease Type II | completed | "NCT04910776 (Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04910776)) |
| March 2, 2026 | [Adcirca® (tadalafil) primary completion](https://sec-api.dev/pdufa/tadalafil) | SNY | Erectile Dysfunction | completed | "NCT06805513 (Actual Use Trial of Tadalafil 5 mg): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06805513)) |
| March 31, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis Without Nasal Polyps | completed | "NCT06691113 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-31 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691113)) |
| April 23, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is April 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm)) |
| April 27, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is April 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex993.htm)) |
| April 29, 2026 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | delayed | "The target action date is April 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm)) |
| May 1, 2026 | [Menacyw conjugate vaccine primary completion](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Infection; Healthy Volunteers | completed | "NCT07135986 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-01 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07135986)) |
| May 13, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Colitis Ulcerative | completed | "NCT05731128 (A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05731128)) |
| May 22, 2026 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05280548 (A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05280548)) |
| June 8, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Lichen Simplex Chronicus | completed | "NCT06687967 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06687967)) |
| June 8, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Lichen Simplex Chronicus | completed | "NCT06687980 (A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06687980)) |
| June 10, 2026 | [Riliprubart primary completion](https://sec-api.dev/pdufa/riliprubart) | SNY |  | completed | "NCT06290128 (A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290128)) |
| June 10, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06407934 (A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06407934)) |
| July 9, 2026 | [Sarclisa (isatuximab-irfc) FDA approval](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761445 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20260709, review_priority STANDARD; sponsor_name SANOFI-AVENTIS U.S. LLC; product SARCLISA ESCENA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761445%22)) |
| July 23, 2026 | [SARCLISA® (isatuximab) PDUFA date](https://sec-api.dev/pdufa/isatuximab) | SNY |  | scheduled | "The revised target action date for the FDA decision is July 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312526180848/d137048dex992.htm)) |
| July 30, 2026 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Crohn's Disease | withdrawn | "NCT06637631 (A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06637631)) |
| August 4, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03974113)) |
| Aug to Nov 2026 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03974113)) |
| August 5, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Coeliac Disease; Celiac Disease | completed | "NCT06557772 (A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06557772)) |
| Aug to Nov 2026 | [Amlitelimab topline data readout](https://sec-api.dev/pdufa/amlitelimab) | SNY | Coeliac Disease; Celiac Disease | scheduled | "NCT06557772 (A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06557772)) |
| August 6, 2026 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Colitis Ulcerative | withdrawn | "NCT06867094 (A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06867094)) |
| September 4, 2026 | [Sar441344 iv primary completion](https://sec-api.dev/pdufa/sar441344-iv) | SNY | Systemic Lupus Erythematosus | completed | "NCT05039840 (Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05039840)) |
| Sep to Dec 2026 | [Sar441344 iv topline data readout](https://sec-api.dev/pdufa/sar441344-iv) | SNY | Systemic Lupus Erythematosus | scheduled | "NCT05039840 (Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05039840)) |
| September 10, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Obstructive Pulmonary Disease | completed | "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208306)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208306)) |
| September 14, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03754790)) |
| Sep to Dec 2026 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03754790)) |
| September 22, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Asthma | withdrawn | "NCT06033833 (Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033833)) |
| September 23, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834347)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834347)) |
| September 24, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834360)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834360)) |
| September 29, 2026 | [Balinatunfib primary completion](https://sec-api.dev/pdufa/balinatunfib) | SNY | Colitis Ulcerative; Crohn's Disease | withdrawn | "NCT07222189 (A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222189)) |
| Oct 2026 to Jan 2027 | [Cerezyme (imiglucerase) topline data readout](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher Disease Type 1; Gaucher Disease Type 3 | scheduled | "NCT02843035 (Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02843035)) |
| October 7, 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Bronchiectasis | completed | "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06280391?tab=results)) |
| October 7, 2026 | [Menacyw conjugate vaccine topline data readout](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) | SNY | Meningococcal Immunisation; Healthy Volunteers | completed | "NCT06284915 (Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-10-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284915?tab=results)) |
| October 2026 | [Cerezyme (imiglucerase) primary completion](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher Disease Type 1; Gaucher Disease Type 3 | delayed | "NCT02843035 (Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02843035)) |
| Nov 2026 to Feb 2027 | [Yellow fever vaccine (live) topline data readout](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | scheduled | "NCT07103148 (A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07103148)) |
| Nov 2026 to Feb 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| November 25, 2026 | [Venglustat PDUFA date](https://sec-api.dev/pdufa/venglustat) | SNY |  | scheduled | "The target action date for the FDA decision is November 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm)) |
| November 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| November 2026 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | scheduled | "NCT07103148 (A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07103148)) |
| Dec 2026 to Mar 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | scheduled | "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500702)) |
| December 2026 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Pneumococcal Infections | scheduled | "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06838000)) |
| Dec 2026 to Mar 2027 | [PCV21 topline data readout](https://sec-api.dev/pdufa/pcv21) | SNY | Pneumococcal Infections | scheduled | "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06838000)) |
| Dec 2026 to Mar 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Crohn's Disease | scheduled | "NCT06958536 (A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958536)) |
| Dec 2026 to Mar 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| December 2026 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Crohn's Disease | scheduled | "NCT06958536 (A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958536)) |
| December 2026 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| December 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | scheduled | "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500702)) |
| Jan to Apr 2027 | [PCV21 topline data readout](https://sec-api.dev/pdufa/pcv21) | SNY | Sickle Cell Disease | scheduled | "NCT07247188 (Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07247188)) |
| January 2027 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Sickle Cell Disease | scheduled | "NCT07247188 (Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07247188)) |
| Feb to May 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Graves' Disease | scheduled | "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984627)) |
| Feb to May 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07170917 (Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07170917)) |
| Feb to May 2027 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424144)) |
| February 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07170917 (Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07170917)) |
| February 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Graves' Disease | scheduled | "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984627)) |
| February 2027 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424144)) |
| Mar to Jun 2027 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662319)) |
| March 2027 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT05662319 (A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662319)) |
| Apr to Jul 2027 | [Isatuximab sar650984 topline data readout](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT03319667 (A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03319667)) |
| Apr to Jul 2027 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111586)) |
| April 2027 | [Isatuximab sc-obds primary completion](https://sec-api.dev/pdufa/isatuximab-sc-obds) | SNY | Plasma Cell Myeloma Refractory | scheduled | "NCT06356571 (A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356571)) |
| Apr to Jul 2027 | [Isatuximab sc-obds topline data readout](https://sec-api.dev/pdufa/isatuximab-sc-obds) | SNY | Plasma Cell Myeloma Refractory | scheduled | "NCT06356571 (A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356571)) |
| Apr to Jul 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06812988 (Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812988)) |
| Apr to Jul 2027 | [SAR444336 topline data readout](https://sec-api.dev/pdufa/sar444336) | SNY | Microscopic Colitis | scheduled | "NCT07156175 (A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-08 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156175)) |
| April 2027 | [Isatuximab sar650984 primary completion](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT03319667 (A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03319667)) |
| April 2027 | [SAR444336 primary completion](https://sec-api.dev/pdufa/sar444336) | SNY | Microscopic Colitis | scheduled | "NCT07156175 (A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-08 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07156175)) |
| April 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06111586 (Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06111586)) |
| April 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06812988 (Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812988)) |
| May to Aug 2027 | [Aubagio (teriflunomide) topline data readout](https://sec-api.dev/pdufa/teriflunomide) | SNY | Multiple Sclerosis | scheduled | "NCT06141473 (Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141473)) |
| May to Aug 2027 | [Pcv21 vaccine topline data readout](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06736041 (Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736041)) |
| May 2027 | [Aubagio (teriflunomide) primary completion](https://sec-api.dev/pdufa/teriflunomide) | SNY | Multiple Sclerosis | scheduled | "NCT06141473 (Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141473)) |
| May 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06736041 (Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736041)) |
| Jun to Sep 2027 | [Fexofenadine (loratadine if not available) topline data readout](https://sec-api.dev/pdufa/fexofenadine-loratadine-if-not-available) | SNY | Pruritus | scheduled | "NCT05263206 (Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263206)) |
| Jun to Sep 2027 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | scheduled | "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06676319)) |
| Jun to Sep 2027 | [Pcv21 vaccine topline data readout](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT07348692 (Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07348692)) |
| June 2027 | [Fexofenadine (loratadine if not available) primary completion](https://sec-api.dev/pdufa/fexofenadine-loratadine-if-not-available) | SNY | Pruritus | scheduled | "NCT05263206 (Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263206)) |
| June 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT07348692 (Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07348692)) |
| June 2027 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Asthma | scheduled | "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06676319)) |
| Jul to Oct 2027 | [Riliprubart topline data readout](https://sec-api.dev/pdufa/riliprubart) | SNY | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06290141 (A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290141)) |
| Jul to Oct 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Sickle Cell Disease | scheduled | "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975865)) |
| Jul to Oct 2027 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07325292)) |
| July 2027 | [Riliprubart primary completion](https://sec-api.dev/pdufa/riliprubart) | SNY | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT06290141 (A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290141)) |
| July 2027 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT07325292 (Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07325292)) |
| July 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Sickle Cell Disease | scheduled | "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975865)) |
| Aug to Nov 2027 | [Pcv21 vaccine topline data readout](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT06975878 (Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975878)) |
| August 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization; Healthy Volunteers | scheduled | "NCT06975878 (Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975878)) |
| Sep to Dec 2027 | [Amlitelimab topline data readout](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241118)) |
| Sep to Dec 2027 | [Pcv21 vaccine topline data readout](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824181 (Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-10 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824181)) |
| Sep to Dec 2027 | [SAR445399 topline data readout](https://sec-api.dev/pdufa/sar445399) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07225569 (A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225569)) |
| September 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824181 (Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-10 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824181)) |
| September 2027 | [SAR445399 primary completion](https://sec-api.dev/pdufa/sar445399) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07225569 (A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225569)) |
| September 2027 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241118)) |
| Oct 2027 to Jan 2028 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | SNY | Prurigo Nodularis | scheduled | "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293053)) |
| Oct 2027 to Jan 2028 | [Pcv21 vaccine topline data readout](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824194 (Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824194)) |
| October 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824194 (Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824194)) |
| October 2027 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Prurigo Nodularis | scheduled | "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293053)) |
| October 2027 | [SAR445399 primary completion](https://sec-api.dev/pdufa/sar445399) | SNY | Non-cystic Fibrosis Bronchiectasis | delayed | "NCT07547436 (A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07547436)) |
| Nov 2027 to Feb 2028 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007962)) |
| November 2027 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007962)) |
| Dec 2027 to Mar 2028 | [Iiv-hd (standalone) topline data readout](https://sec-api.dev/pdufa/iiv-hd-standalone) | SNY | Immunization; Healthy Volunteers; COVID-19 Immunization | scheduled | "NCT07890454 (Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890454)) |
| December 2027 | [Iiv-hd (standalone) primary completion](https://sec-api.dev/pdufa/iiv-hd-standalone) | SNY | Immunization; Healthy Volunteers; COVID-19 Immunization | scheduled | "NCT07890454 (Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890454)) |
| March 2028 | [Sarilumab sar153191 (regn88) primary completion](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) | SNY | Juvenile Idiopathic Arthritis | scheduled | "NCT02991469 (A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02991469)) |
| Mar to Jun 2028 | [Sarilumab sar153191 (regn88) topline data readout](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) | SNY | Juvenile Idiopathic Arthritis | scheduled | "NCT02991469 (A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02991469)) |
| Mar to Jun 2028 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141486)) |
| Mar to Jun 2028 | [TZIELD® (teplizumab) topline data readout](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06791291)) |
| Mar to Jun 2028 | [Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) topline data readout](https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con) | SNY | Meningococcal Infection; Healthy Volunteers | scheduled | "NCT07710872 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07710872)) |
| March 2028 | [TZIELD® (teplizumab) primary completion](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06791291)) |
| March 2028 | [Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) primary completion](https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con) | SNY | Meningococcal Infection; Healthy Volunteers | scheduled | "NCT07710872 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07710872)) |
| March 2028 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141486)) |
| May to Aug 2028 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Autoimmune Haemolytic Anaemia | scheduled | "NCT07086976 (A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07086976)) |
| May to Aug 2028 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07184996 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184996)) |
| May to Aug 2028 | [Dupilumab coformulated with berahyaluronidase alfa topline data readout](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) | SNY | Dermatitis Atopic | scheduled | "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919899)) |
| May 2028 | [Dupilumab coformulated with berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) | SNY | Dermatitis Atopic | scheduled | "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919899)) |
| May 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07184996 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184996)) |
| May 2028 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Autoimmune Haemolytic Anaemia | scheduled | "NCT07086976 (A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07086976)) |
| Jun to Sep 2028 | [SAR447537 topline data readout](https://sec-api.dev/pdufa/sar447537) | SNY | Alpha 1-Antitrypsin Deficiency; Emphysema | scheduled | "NCT05897424 (Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05897424)) |
| Jun to Sep 2028 | [TZIELD® (teplizumab) topline data readout](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088068)) |
| Jun to Sep 2028 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immunoglobulin G4 Related Disease | scheduled | "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190196)) |
| Jun to Sep 2028 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Hidradenitis | scheduled | "NCT07812116 (A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07812116)) |
| June 2028 | [TZIELD® (teplizumab) primary completion](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT07088068 (A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07088068)) |
| June 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Hidradenitis | scheduled | "NCT07812116 (A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07812116)) |
| June 2028 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immunoglobulin G4 Related Disease | scheduled | "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190196)) |
| June 2028 | [SAR447537 primary completion](https://sec-api.dev/pdufa/sar447537) | SNY | Alpha 1-Antitrypsin Deficiency; Emphysema | scheduled | "NCT05897424 (Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05897424)) |
| Jul to Oct 2028 | [Acne mrna (messenger ribonucleic acid) vaccine topline data readout](https://sec-api.dev/pdufa/acne-mrna-messenger-ribonucleic-acid-vaccine) | SNY | Acne | scheduled | "NCT07756957 (Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-19 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756957)) |
| Jul to Oct 2028 | [Bivalent rsv+hmpv protein vaccine topline data readout](https://sec-api.dev/pdufa/bivalent-rsv-hmpv-protein-vaccine) | SNY | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | scheduled | "NCT07810010 (Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07810010)) |
| July 2028 | [Bivalent rsv+hmpv protein vaccine primary completion](https://sec-api.dev/pdufa/bivalent-rsv-hmpv-protein-vaccine) | SNY | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | scheduled | "NCT07810010 (Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07810010)) |
| July 2028 | [Acne mrna (messenger ribonucleic acid) vaccine primary completion](https://sec-api.dev/pdufa/acne-mrna-messenger-ribonucleic-acid-vaccine) | SNY | Acne | scheduled | "NCT07756957 (Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-19 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756957)) |
| Aug to Nov 2028 | [SAR445877 topline data readout](https://sec-api.dev/pdufa/sar445877) | SNY | Gastric Cancer; Oesophageal Carcinoma | scheduled | "NCT07692204 (A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692204)) |
| August 2028 | [SAR445877 primary completion](https://sec-api.dev/pdufa/sar445877) | SNY | Gastric Cancer; Oesophageal Carcinoma | scheduled | "NCT07692204 (A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692204)) |
| Sep to Dec 2028 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143891)) |
| Sep to Dec 2028 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116031)) |
| Sep to Dec 2028 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07185009 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185009)) |
| September 2028 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Ulcerative Colitis | scheduled | "NCT07185009 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07185009)) |
| September 2028 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116031)) |
| September 2028 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143891)) |
| Nov 2028 to Feb 2029 | [Isatuximab intravenous (iv) topline data readout](https://sec-api.dev/pdufa/isatuximab-intravenous-iv) | SNY | Plasma Cell Myeloma | scheduled | "NCT05669989 (International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669989)) |
| November 2028 | [Isatuximab intravenous (iv) primary completion](https://sec-api.dev/pdufa/isatuximab-intravenous-iv) | SNY | Plasma Cell Myeloma | scheduled | "NCT05669989 (International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669989)) |
| Dec 2028 to Mar 2029 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | SNY | Wheezing; Asthma | scheduled | "NCT06191315 (Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-12-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06191315)) |
| December 2028 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Wheezing; Asthma | scheduled | "NCT06191315 (Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-12-21 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06191315)) |
| Jan to Apr 2029 | [Amlitelimab topline data readout](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05492578)) |
| Jan to Apr 2029 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Lung Transplant Rejection | scheduled | "NCT06082037 (A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082037)) |
| January 2029 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05492578)) |
| January 2029 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Lung Transplant Rejection | scheduled | "NCT06082037 (A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082037)) |
| Feb to May 2029 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914908)) |
| February 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914908)) |
| Apr to Jul 2029 | [Tolebrutinib topline data readout](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | scheduled | "NCT06372145 (A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06372145)) |
| April 2029 | [Tolebrutinib primary completion](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | scheduled | "NCT06372145 (A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06372145)) |
| May to Aug 2029 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Crohn's Disease | scheduled | "NCT07184931 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184931)) |
| May 2029 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Crohn's Disease | scheduled | "NCT07184931 (An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184931)) |
| Jun to Sep 2029 | [Kevzara (sarilumab) topline data readout](https://sec-api.dev/pdufa/sarilumab) | SNY | Polymyalgia Rheumatica | scheduled | "NCT07286214 (Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286214)) |
| June 2029 | [Kevzara (sarilumab) primary completion](https://sec-api.dev/pdufa/sarilumab) | SNY | Polymyalgia Rheumatica | scheduled | "NCT07286214 (Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286214)) |
| Jul to Oct 2029 | [SAR448851 topline data readout](https://sec-api.dev/pdufa/sar448851) | SNY | Dementia, Alzheimer's Type; Alzheimer's Disease | scheduled | "NCT07688213 (A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07688213)) |
| July 2029 | [SAR448851 primary completion](https://sec-api.dev/pdufa/sar448851) | SNY | Dementia, Alzheimer's Type; Alzheimer's Disease | scheduled | "NCT07688213 (A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07688213)) |
| Aug to Nov 2029 | [Duvakitug topline data readout](https://sec-api.dev/pdufa/duvakitug) | SNY | Crohn's Disease | scheduled | "NCT07184944 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184944)) |
| Aug to Nov 2029 | [Qfitlia™ (fitusiran) topline data readout](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285460)) |
| Aug to Nov 2029 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Kidney Transplant Rejection | scheduled | "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412470)) |
| August 2029 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | scheduled | "NCT07285460 (A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07285460)) |
| August 2029 | [Duvakitug primary completion](https://sec-api.dev/pdufa/duvakitug) | SNY | Crohn's Disease | scheduled | "NCT07184944 (A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184944)) |
| August 2029 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Kidney Transplant Rejection | scheduled | "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412470)) |
| Sep to Dec 2029 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07771439)) |
| September 2029 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07771439)) |
| Oct 2029 to Jan 2030 | [Riliprubart prefilled pen (pfp) topline data readout](https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp) | SNY | Polyneuropathy, Inflammatory Demyelinating, Chronic | scheduled | "NCT06859099 (Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-10-03 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859099)) |
| October 2029 | [Riliprubart prefilled pen (pfp) primary completion](https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp) | SNY | Polyneuropathy, Inflammatory Demyelinating, Chronic | scheduled | "NCT06859099 (Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-10-03 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859099)) |
| Nov 2029 to Feb 2030 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190209)) |
| Nov 2029 to Feb 2030 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190222)) |
| November 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190209)) |
| November 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190222)) |
| Jan to Apr 2030 | [Cerezyme (imiglucerase) topline data readout](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher's Disease Type III | scheduled | "NCT07927140 (The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07927140)) |
| January 2030 | [Cerezyme (imiglucerase) primary completion](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher's Disease Type III | scheduled | "NCT07927140 (The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07927140)) |
| Oct 2030 to Jan 2031 | [Isatuximab sar650984 topline data readout](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT04270409 (Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04270409)) |
| October 2030 | [Isatuximab sar650984 primary completion](https://sec-api.dev/pdufa/isatuximab-sar650984) | SNY | Plasma Cell Myeloma | scheduled | "NCT04270409 (Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04270409)) |

## Drugs

- [Acne mrna (messenger ribonucleic acid) vaccine](https://sec-api.dev/pdufa/acne-mrna-messenger-ribonucleic-acid-vaccine): Acne
- [Fabrazyme (agalsidase beta)](https://sec-api.dev/pdufa/agalsidase-beta): 
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab): Coeliac Disease, Dermatitis Atopic, Alopecia Areata, Asthma
- [Avalglucosidase alfa](https://sec-api.dev/pdufa/avalglucosidase-alfa): Glycogen Storage Disease Type II
- [Nexviazyme (avalglucosidase alfa-ngpt)](https://sec-api.dev/pdufa/avalglucosidase-alfa-ngpt): 
- [AYVAKIT® (avapritinib)](https://sec-api.dev/pdufa/avapritinib): advanced sm in june 2021 and indolent sm in may 2023
- [Balinatunfib](https://sec-api.dev/pdufa/balinatunfib): Colitis Ulcerative
- [Belumosudil](https://sec-api.dev/pdufa/belumosudil): Lung Transplant Rejection, Chronic Graft Versus Host Disease
- [Bivalent rsv+hmpv protein vaccine](https://sec-api.dev/pdufa/bivalent-rsv-hmpv-protein-vaccine): Respiratory Syncytial Virus
- [Bivv020 (sar445088)](https://sec-api.dev/pdufa/bivv020-sar445088): Transplant Rejection
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig): Hidradenitis Suppurativa, Type 1 Diabetes Mellitus, Ulcerative Colitis, Crohn's Disease
- [Jevtana Kit (cabazitaxel)](https://sec-api.dev/pdufa/cabazitaxel): 
- [Clolar (clofarabine)](https://sec-api.dev/pdufa/clofarabine): 
- [Doxercalciferol (gz427397)](https://sec-api.dev/pdufa/doxercalciferol-gz427397): Secondary Hyperparathyroidism-Chronic Kidney Disease
- [Multaq (dronedarone hydrochloride)](https://sec-api.dev/pdufa/dronedarone): 
- [Dupilumab coformulated with berahyaluronidase alfa](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa): Dermatitis Atopic
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug): Ulcerative Colitis, Crohn's Disease, Hidradenitis
- [Eliglustat gz385660](https://sec-api.dev/pdufa/eliglustat-gz385660): Gaucher's Disease Type I
- [Fexinidazole (fexinidazole)](https://sec-api.dev/pdufa/fexinidazole): 
- [Fexofenadine (loratadine if not available)](https://sec-api.dev/pdufa/fexofenadine-loratadine-if-not-available): Pruritus
- [Qfitlia™ (fitusiran)](https://sec-api.dev/pdufa/fitusiran): To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release, Hemophilia
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab): Type 1 Diabetes Mellitus, Multiple Sclerosis, Kidney Transplant Rejection
- [Iiv-hd (standalone)](https://sec-api.dev/pdufa/iiv-hd-standalone): Immunization
- [Cerezyme (imiglucerase)](https://sec-api.dev/pdufa/imiglucerase): Gaucher's Disease Type III, Gaucher Disease Type 1
- [Merilog (insulin aspart-szjj)](https://sec-api.dev/pdufa/insulin-aspart-szjj): 
- [Soliqua 100/33 (insulin glargine; lixisenatide)](https://sec-api.dev/pdufa/insulin-glargine-lixisenatide): 
- [Admelog (insulin lispro)](https://sec-api.dev/pdufa/insulin-lispro): 
- [SARCLISA® (isatuximab)](https://sec-api.dev/pdufa/isatuximab): Relapsed/Refractory Multiple Myeloma
- [Isatuximab intravenous (iv)](https://sec-api.dev/pdufa/isatuximab-intravenous-iv): Plasma Cell Myeloma
- [Sarclisa (isatuximab-irfc)](https://sec-api.dev/pdufa/isatuximab-irfc): 
- [Isatuximab sar650984](https://sec-api.dev/pdufa/isatuximab-sar650984): Plasma Cell Myeloma
- [Isatuximab sc-obds](https://sec-api.dev/pdufa/isatuximab-sc-obds): Plasma Cell Myeloma Refractory
- [Itepekimab](https://sec-api.dev/pdufa/itepekimab): copd in two phase 3 studies aerify-1
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340): Bronchiectasis, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
- [Adlyxin (lixisenatide)](https://sec-api.dev/pdufa/lixisenatide): 
- [Low dose (ld) rsvt vaccine](https://sec-api.dev/pdufa/low-dose-ld-rsvt-vaccine): RSV Immunisation
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig): Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Dermatitis Atopic, Asthma
- [Menacyw conjugate vaccine](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine): Meningococcal Immunisation, Meningococcal Infection
- [Meningococcal polysaccharide (serogroups a, c, y, and w) tetanus toxoid conjugate vaccine](https://sec-api.dev/pdufa/meningococcal-polysaccharide-serogroups-a-c-y-and-w-tetanus-toxoid-conjugate-vac): Meningococcal Immunisation
- [Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa)](https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con): Meningococcal Infection
- [Nvx-cov2705](https://sec-api.dev/pdufa/nvx-cov2705): COVID-19
- [Xenpozyme (olipudase alfa-rpcp)](https://sec-api.dev/pdufa/olipudase-alfa-rpcp): 
- [PCV21](https://sec-api.dev/pdufa/pcv21): Pneumococcal Infections, Sickle Cell Disease
- [Pcv21 vaccine](https://sec-api.dev/pdufa/pcv21-vaccine): Pneumococcal Immunization
- [Riliprubart](https://sec-api.dev/pdufa/riliprubart): Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- [Riliprubart prefilled pen (pfp)](https://sec-api.dev/pdufa/riliprubart-prefilled-pen-pfp): Polyneuropathy, Inflammatory Demyelinating, Chronic
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib): Immune Thrombocytopenia, Graves' Disease, Focal Segmental Glomerulosclerosis, Sickle Cell Disease, Immunoglobulin G4 Related Disease, Autoimmune Haemolytic Anaemia
- [Rsvt vaccine](https://sec-api.dev/pdufa/rsvt-vaccine): RSV Immunization, RSV Immunisation
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv): Systemic Lupus Erythematosus
- [SAR441566](https://sec-api.dev/pdufa/sar441566): Rheumatoid Arthritis, Crohn's Disease, Colitis Ulcerative
- [SAR443122](https://sec-api.dev/pdufa/sar443122): Colitis Ulcerative
- [SAR444336](https://sec-api.dev/pdufa/sar444336): Microscopic Colitis
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474): Atopic Dermatitis, Hidradenitis Suppurativa
- [SAR445399](https://sec-api.dev/pdufa/sar445399): Non-cystic Fibrosis Bronchiectasis, Hidradenitis Suppurativa
- [SAR445877](https://sec-api.dev/pdufa/sar445877): Gastric Cancer
- [SAR447537](https://sec-api.dev/pdufa/sar447537): Alpha 1-Antitrypsin Deficiency
- [SAR448851](https://sec-api.dev/pdufa/sar448851): Dementia, Alzheimer's Type
- [Kevzara (sarilumab)](https://sec-api.dev/pdufa/sarilumab): Polymyalgia Rheumatica
- [Sarilumab sar153191 (regn88)](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88): Juvenile Idiopathic Arthritis
- [Adcirca® (tadalafil)](https://sec-api.dev/pdufa/tadalafil): Erectile Dysfunction
- [TZIELD® (teplizumab)](https://sec-api.dev/pdufa/teplizumab): Type 1 Diabetes Mellitus
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide): Multiple Sclerosis
- [Thyrogen (thyrotropin alfa)](https://sec-api.dev/pdufa/thyrotropin-alfa): 
- [Tolebrutinib](https://sec-api.dev/pdufa/tolebrutinib): Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- [Caprelsa (vandetanib)](https://sec-api.dev/pdufa/vandetanib): 
- [Venglustat](https://sec-api.dev/pdufa/venglustat): 
- [Venglustat (gz402671)](https://sec-api.dev/pdufa/venglustat-gz402671): Fabry Disease
- [Yellow fever vaccine (live)](https://sec-api.dev/pdufa/yellow-fever-vaccine-live): Yellow Fever, Yellow Fever Immunization

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sny/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SNY catalysts: Sanofi PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sny/catalysts

```bibtex
@misc{secapidev_companies_sny_catalysts_20261116,
  title        = {SNY catalysts: Sanofi PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sny/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sny_catalysts_20261116","title":"SNY catalysts: Sanofi PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sny/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
